Demand is not the main risk; sequencing is. Core Scientific needs
ERCOT progress, construction, and financing to line up closely enough that contracted megawatts become billed cash flow before leverage, concentration or timeline slippage erode negotiating power. The upside is real because each delivered campus improves credibility and financeability, but missed dates can keep the equity stuck between miner and digital-infrastructure valuations.